Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NebuPEP: Amikacin Nebulization and PEP in Cystic Fibrosis
NCT02535130Unknown
- Start
- Aug 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of amikacin in cystic fibrosis (CF). Primary endpoint: Urinary excretion of amikacin at 24 hours. Status: unknown.
02
Drugs
amikacin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02535130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02535130.